Figure 2.

Convergence of new knowledge distilled from clinical trials and regenerative science has expedited the stratification of responders versus non-responders to biotherapy while decoding the molecular underpinnings associated with repair capacity. The era of “clinomics” leverages clinically available biospecimens, including clinical trial biobanked stem cells, to help resolve through ‘omics methodologies the core components underlying therapeutic bioactivity. Iterative, integrated analysis guides the development of next generation biotherapeutics endowed with regenerative biopotency and optimized to achieve consistent outcomes in defined candidate populations.